Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH

por Poulin, Y, Crowley, JJ, Langley, RG, Unnebrink, K, Goldblum, OM, Valdecantos, WC
Publicado 2014

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, control...

por Thaçi, D., Kimball, A., Foley, P., Poulin, Y., Levi, E., Chen, R., Feldman, S.R.
Publicado 2016

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–asses...

por Warren, R.B., Blauvelt, A., Poulin, Y., Beeck, S., Kelly, M., Wu, T., Geng, Z., Paul, C.
Publicado 2020

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients...

por Papp, KA, Barber, K, Bissonnette, R, Bourcier, M, Lynde, CW, Poulin, Y, Shelton, J, Toole, J, Vieira, A, Poulin-Costello, M
Publicado 2015

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

por Papp, K.A., Barber, K., Bissonnette, R., Bourcier, M., Lynde, C.W., Poulin, Y., Shelton, J., Garces, K., Toole, J., Poulin‐Costello, M.
Publicado 2015

Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial

por Elewski, B.E., Baker, C.S., Crowley, J.J., Poulin, Y., Okun, M.M., Calimlim, B., Geng, Z., Reyes Servin, O., Rich, P.A.
Publicado 2019

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

por Gordon, K.B., Warren, R.B., Gottlieb, A.B., Blauvelt, A., Thaçi, D., Leonardi, C., Poulin, Y., Boehnlein, M., Brock, F., Ecoffet, C., Reich, K.
Publicado 2020

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

por Blauvelt, A., Papp, K.A., Sofen, H., Augustin, M., Yosipovitch, G., Katoh, N., Mrowietz, U., Ohtsuki, M., Poulin, Y., Shrom, D., Burge, R., See, K., Mallbris, L., Gordon, K.B.
Publicado 2017

Corticosteroids for critically ill patients: an international survey of intensivists

por Lamontagne, F, Adhikari, N, Cook, D, Koo, KK, Lauzier, F, Burns, KE, Douglas, I, Turgeon, AF, Quiroz, H, Poulin, Y, Choong, K, Ferguson, N, Kho, ME, Duffett, M, Chant, C, Lesur, O, Meade, MO
Publicado 2012

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)...

por Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J.‐P., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., Lesiak, A., Kircik, L., Cho, S.H., Herranz, P., Cork, M.J., Peris, K., Steffensen, L.A., Bang, B., Kuznetsova, A., Jensen, T.N., Østerdal, M.L., Simpson, E.L.
Publicado 2020